Graff L, Burnel D
Laboratoire de Chimie Generale Appliquee a la Medecine, Faculte de Medecine, Universite Henri Poincare, France.
Res Commun Mol Pathol Pharmacol. 1995 Dec;90(3):389-401.
The aim of this study was to study a possible new non-aluminum phosphate-binder to limit hyperphosphatemia in patients with renal failure. Zirconyl chloride octahydrate was evaluated as a dietary phosphate binder in rats. Aluminum chloride hexahydrate was used as a reference. Animals were divided into six groups (6 animals per group): One - control group (C), two - aluminum groups (Al1 and Al2) and three - zirconium groups (Zr1, Zr2 and Zr3) receiving different doses of zirconyl chloride octahydrate. Urines were collected during the experimental period. At the end of the treatment, the animals were sacrified and plasma and different organs were collected (liver, spleen, kidneys, brain and femur). Determination of phosphorus and calcium levels in plasma indicated that zirconyl chloride octahydrate yielded as good results as aluminum chloride hexahydrate did. Zirconyl chloride octahydrate significantly (p<0.01) reduced bone phosphorus burden. Urinary excretion of phosphorus indicated a severe phosphorus depletion in all treatments. Not even traces of zirconium could be determined in the different tissues, in urines or in plasma. Consequently, it is important to carry out experiments with zirconium compounds in order to develop non-aluminum-containing phosphate binders.
本研究的目的是研究一种可能的新型非铝磷酸盐结合剂，以限制肾衰竭患者的高磷血症。八水合氧氯化锆在大鼠中作为膳食磷酸盐结合剂进行评估。六水合氯化铝用作对照。动物分为六组（每组6只动物）：一组为对照组（C），两组为铝组（Al1和Al2），三组为锆组（Zr1、Zr2和Zr3），接受不同剂量的八水合氧氯化锆。在实验期间收集尿液。治疗结束时，处死动物并收集血浆和不同器官（肝脏、脾脏、肾脏、大脑和股骨）。血浆中磷和钙水平的测定表明，八水合氧氯化锆产生的结果与六水合氯化铝一样好。八水合氧氯化锆显著（p<0.01）降低了骨磷负荷。磷的尿排泄表明所有治疗中均存在严重的磷缺乏。在不同组织、尿液或血浆中均未检测到锆的痕迹。因此，开展锆化合物实验以开发不含铝的磷酸盐结合剂很重要。
